Case Report
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Mar 26, 2022; 10(9): 2836-2843
Published online Mar 26, 2022. doi: 10.12998/wjcc.v10.i9.2836
Sequential occurrence of T790M mutation and small cell lung cancer transformation in EGFR-positive lung adenocarcinoma: A case report
Er Hong, Xi-Er Chen, Jia Mao, Jing-Jing Zhou, Ling Chen, Jia-Yi Xu, Wei Tao
Er Hong, Xi-Er Chen, Jia Mao, Jing-Jing Zhou, Ling Chen, Jia-Yi Xu, Department of Respiratory, Ningbo Municipal Hospital of Traditional Chinese Medicine, Affiliated to Zhejiang Chinese Medical University, Ningbo 315000, Zhejiang Province, China
Wei Tao, Department of Radiology, Ningbo Municipal Hospital of Traditional Chinese Medicine, Affiliated to Zhejiang Chinese Medical University, Ningbo 315000, Zhejiang Province, China
Author contributions: Hong E, Chen XE and Tao W collaborated in data collection, literature review and writing the manuscript; Mao J, Zhou JJ analyzed the data from the patient; Chen L and Xu JY were responsible for the treatment and management of the patient; All authors read and approved the final manuscript.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wei Tao, MD, Chief Doctor, Department of Radiology, Ningbo Municipal Hospital of Traditional Chinese Medicine, Affiliated to Zhejiang Chinese Medical University, No. 819 Liyuan North Road, Haishu District, Ningbo 315000, Zhejiang Province, China. 70225027@qq.com
Received: August 16, 2021
Peer-review started: August 16, 2021
First decision: November 6, 2021
Revised: November 17, 2021
Accepted: February 16, 2022
Article in press: February 16, 2022
Published online: March 26, 2022
Processing time: 218 Days and 1.5 Hours
Core Tip

Core Tip: The emergence of secondary drug resistance seriously affects the efficacy of tyrosine kinase inhibitor (TKI) treatment and prognosis of patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer. EGFR-T790M mutation and tumor phenotype transformation are common drug resistance mechanisms in the first-generation TKI treatment process. Thus, it is necessary to determine the potential mechanisms using multiple biopsy methods with the aim of selecting appropriate and effective therapeutic drugs and extending the survival of patients with lung cancer.